Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $216M | $-139M | $-220M | $-110M | -67.4% | 8.7% | 1066.5% |
| 2024 | $199M | $-31M | $-19M | $-16M | -3.5% | 3.2% | -853.3% |
| 2023 | $193M | $-10M | $3M | $12M | 0.5% | -24.3% | -60.0% |
| 2022 | $254M | $9M | $6M | $31M | 1.2% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 254.38 | 192.64 | 198.77 | 216.10 |
| Operating Revenue | - | 254.38 | 192.64 | 198.77 | 216.10 |
| Cost Of Revenue | - | 24.28 | 14.80 | 11.31 | 13.04 |
| Gross Profit | - | 230.10 | 177.84 | 187.46 | 203.06 |
| Operating Expense | - | 223.77 | 191.80 | 228.12 | 354.23 |
| Research And Development | - | 85.77 | 76.82 | 74.43 | 109.27 |
| Selling General And Administration | - | 136.49 | 112.88 | 146.41 | 237.95 |
| Total Expenses | - | 248.05 | 206.59 | 239.43 | 367.27 |
| Operating Income | - | 6.33 | -13.95 | -40.66 | -151.17 |
| Total Operating Income As Reported | - | 6.33 | -13.95 | -40.66 | -151.17 |
| EBITDA | - | 9.06 | -9.62 | -30.86 | -139.25 |
| Normalized EBITDA | - | 9.06 | -9.62 | -30.86 | -139.25 |
| EBIT | - | 6.33 | -13.95 | -40.66 | -151.17 |
| Other Non Operating Income Expenses | - | 4.97 | 20.29 | 17.74 | 12.52 |
| Other Income Expense | - | 4.97 | 20.29 | 17.74 | 12.52 |
| Pretax Income | - | 11.30 | 6.34 | -22.92 | -138.65 |
| Tax Provision | - | 5.03 | 3.83 | -4.02 | 81.83 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | 6.28 | 2.51 | -18.90 | -220.47 |
| Net Income From Continuing And Discontinued Operation | - | 6.28 | 2.51 | -18.90 | -220.47 |
| Net Income From Continuing Operation Net Minority Interest | - | 6.28 | 2.51 | -18.90 | -220.47 |
| Net Income | - | 6.28 | 2.51 | -18.90 | -220.47 |
| Net Income Common Stockholders | - | 6.28 | 2.51 | -18.90 | -220.47 |
| Net Income Including Noncontrolling Interests | - | 6.28 | 2.51 | -18.90 | -220.47 |
| Normalized Income | - | 6.28 | 2.51 | -18.90 | -220.47 |
| Diluted NI Availto Com Stockholders | - | 6.28 | 2.51 | -18.90 | -220.47 |
| Basic Average Shares | - | 56.46 | 57.38 | 58.15 | 58.93 |
| Diluted Average Shares | - | 56.98 | 57.56 | 58.15 | 58.93 |
| Reconciled Depreciation | - | 2.73 | 4.33 | 9.80 | 11.92 |
| Reconciled Cost Of Revenue | - | 23.06 | 12.55 | 8.79 | 8.13 |
| Depreciation Amortization Depletion Income Statement | - | 1.52 | 2.09 | 7.27 | 7.01 |
| Depreciation And Amortization In Income Statement | - | 1.52 | 2.09 | 7.27 | 7.01 |
| Amortization | - | 1.52 | 2.09 | 7.27 | 7.01 |
| Amortization Of Intangibles Income Statement | - | 1.52 | 2.09 | 7.27 | 7.01 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc.this co. | VNDA | $376M | - | 1.15 | -67.4% | - |
| OmniAb, Inc. | OABI | $386M | -5.95 | 1.44 | -24.3% | -8.06 |
| Compass Therapeutics, Inc. | CMPX | $384M | -5.77 | 1.95 | -33.8% | -5.08 |
| Benitec Biopharma Inc. | BNTC | $380M | -10.01 | 3.90 | -39.0% | -6.83 |
| Viemed Healthcare, Inc. | VMD | $377M |
| - |
| - |
| - |
| - |
| - |
| - |
| 25.26 |
| 2.67 |
| 10.6% |
| 7.36 |
| CapsoVision, Inc. | CV | $377M | -14.88 | 28.41 | -190.9% | -14.73 |
| Lexeo Therapeutics, Inc. | LXEO | $375M | -3.75 | 1.52 | -40.5% | -3.28 |
| Delcath Systems, Inc. | DCTH | $372M | 137.96 | 3.35 | 2.4% | 327.03 |
| Perspective Therapeutics, Inc. | CATX | $371M | -3.59 | 1.79 | -49.8% | -3.41 |
| Peer Median | - | -4.76 | 2.31 | -36.4% | -4.24 | |
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historically, Jun has averaged the highest return (+9.6%); Jul the lowest (-10.1%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.5%Negative MonthJan 2026: -14.51% | +18.2%Positive MonthFeb 2026: +18.17% | -22.4%Negative MonthMar 2026: -22.45% | +2.7%Positive MonthApr 2026: +2.75% | -9.2%Negative MonthMay 2026: -9.15% | -5.1%Negative MonthJun 2026: -5.12% | -16.7%Negative MonthJul 2026: -16.67% | +9.2%*Positive MonthAug 2026: +9.22% | — | — | — | — |
| 2025 | -7.9%Negative MonthJan 2025: -7.93% | +7.9%Positive MonthFeb 2025: +7.94% | -3.6%Negative MonthMar 2025: -3.57% | -1.7%Neutral MonthApr 2025: -1.74% | -3.8%Negative MonthMay 2025: -3.77% | +8.8%Positive MonthJun 2025: +8.76% | -9.7%Negative MonthJul 2025: -9.75% | +11.0%Positive MonthAug 2025: +11.03% | +5.5%Positive MonthSep 2025: +5.50% | -12.8%Negative MonthOct 2025: -12.83% | +23.2%Positive MonthNov 2025: +23.22% | +64.6%Positive MonthDec 2025: +64.55% |
| 2024 | -14.7%Negative MonthJan 2024: -14.69% | +24.2%Positive MonthFeb 2024: +24.17% | -8.1%Negative MonthMar 2024: -8.05% | +15.8%Positive MonthApr 2024: +15.82% | +7.4%Positive MonthMay 2024: +7.35% | +10.6%Positive MonthJun 2024: +10.57% | +3.4%Positive MonthJul 2024: +3.36% | -9.4%Negative MonthAug 2024: -9.42% | -11.3%Negative MonthSep 2024: -11.34% | -0.9%Neutral MonthOct 2024: -0.85% | +10.8%Positive MonthNov 2024: +10.75% | -7.0%Negative MonthDec 2024: -6.99% |
| 2023 | +3.9%Positive MonthJan 2023: +3.92% | -16.1%Negative MonthFeb 2023: -16.15% | +5.4%Positive MonthMar 2023: +5.43% | -9.6%Negative MonthApr 2023: -9.57% | -3.1%Negative MonthMay 2023: -3.09% | +10.8%Positive MonthJun 2023: +10.76% | -12.3%Negative MonthJul 2023: -12.29% | -10.2%Negative MonthAug 2023: -10.21% | -16.8%Negative MonthSep 2023: -16.76% | +1.4%Neutral MonthOct 2023: +1.39% | -15.1%Negative MonthNov 2023: -15.07% | +13.4%Positive MonthDec 2023: +13.44% |
| 2022 | -3.4%Negative MonthJan 2022: -3.38% | -25.1%Negative MonthFeb 2022: -25.07% | -0.4%Neutral MonthMar 2022: -0.44% | -12.3%Negative MonthApr 2022: -12.29% | -0.9%Neutral MonthMay 2022: -0.91% | +10.9%Positive MonthJun 2022: +10.89% | -1.1%Neutral MonthJul 2022: -1.10% | -1.9%Neutral MonthAug 2022: -1.86% | -6.6%Negative MonthSep 2022: -6.62% | +6.0%Positive MonthOct 2022: +5.97% | +4.2%Positive MonthNov 2022: +4.20% | -32.3%Negative MonthDec 2022: -32.26% |
| 2021 | — | — | — | — | +6.6%Positive MonthMay 2021: +6.57% | +21.6%Positive MonthJun 2021: +21.59% | -24.2%Negative MonthJul 2021: -24.17% | +2.6%Positive MonthAug 2021: +2.64% | +2.4%Positive MonthSep 2021: +2.39% | -0.1%Neutral MonthOct 2021: -0.12% | -5.4%Negative MonthNov 2021: -5.37% | -3.1%Negative MonthDec 2021: -3.15% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
